CMS Overview

Focusing on unmet clinical needs, we fuel innovation through the dual engines of collaborative R&D and in-house R&D. We strategically build an innovation pipeline centered on first-in-class (FIC) and best-in-class* (BIC) products, delivering more breakthrough disease solutions for patients.

We have a robust management system and professional team capable of overseeing key milestones across the entire life cycle of innovative products, along with extensive specialty-focused networks and resources, as well as profound market insights. This enables us to accurately identify and tap into unmet clinical needs, efficiently advance the pre-clinical/clinical research, development and commercialization of innovative products, empowering the highly efficient translation of scientific research outcomes into clinical practice.

We are deeply committed to specialty therapeutic areas, including cardio-cerebrovascular, central nervous system, gastroenterology, metabolic diseases, ophthalmology and skin health. Equipped with a medical-driven, highly efficient commercialization system, we further boost economies of scale through independent operation of specialty business lines, and cultivate leading players in certain specialty areas. Among our specialty business lines, Dermavon has developed into China’s leading innovative pharmaceutical company specialized in skin health, and is proposed for an independent listing on the SEHK.

Meanwhile, we consistently drive the industrial internationalization development — operating and expanding our integrated R&D, manufacturing, and commercialization value chain in Southeast Asia and the Middle East to capture incremental growth in emerging markets, supporting the Group’s high-quality and sustainable development.

*Best-in-class: innovative products with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems